Immunotherapy in urothelial cancer: current status and future directions

被引:10
作者
Piombino, Claudia [1 ]
Tonni, Elena [1 ]
Oltrecolli, Marco [1 ]
Pirola, Marta [1 ]
Pipitone, Stefania [1 ]
Baldessari, Cinzia [1 ]
Dominici, Massimo [1 ]
Sabbatini, Roberto [1 ]
Vitale, Maria Giuseppa [1 ]
机构
[1] Univ Hosp Modena, Dept Oncol & Hematol, I-41124 Modena, Italy
关键词
Antibody-drug conjugates; atezolizumab; avelumab; durvalumab; immune checkpoint inhibitors; nivolumab; pembrolizumab; urothelial cancer; INVASIVE BLADDER-CANCER; BACILLUS-CALMETTE-GUERIN; SACITUZUMAB GOVITECAN SG; OPEN-LABEL; PATIENTS PTS; PHASE-II; CHECKPOINT INHIBITOR; SINGLE-ARM; LONG-TERM; MICROSATELLITE INSTABILITY;
D O I
10.1080/14737140.2023.2265572
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionSince 2016, the progressive use of immune checkpoint inhibitors (ICIs) starting from second-line treatment has led to an improvement in overall survival in locally advanced and metastatic urothelial cancer (UC). Clinical trials are underway testing the role of ICIs since the first stages of the disease, alone or in combination with standard therapies.Areas coveredThis review summarizes the current updated evidence regarding the role of ICIs in the different stages of UC, the ongoing clinical trials exploring the potential benefit of immunotherapy alone or in combination with standard-of-care therapies, as well as the promising association of ICIs with antibody-drug conjugates (ADCs).Expert opinionIn the first-line setting, ICIs alone in platinum-unfit patients have shown unconvincing results; the ongoing EV-302 trial will probably suggest enfortumab vedotin plus pembrolizumab as a new effective option. The optimal duration of maintenance immunotherapy is still to be determined, finding a balance with the risk-benefit profile. The clinical benefit of ICIs as second-line treatment is limited to a subset of patients that cannot be definitively established yet. In the next 5 years, a lot of new ADCs will likely emerge for the treatment of UC.
引用
收藏
页码:1141 / 1155
页数:15
相关论文
共 50 条
  • [21] The Role of Traditional Chinese Medicine in Cancer Immunotherapy: Current Status and Future Directions
    Xie, Jinxin
    Huang, Huiming
    Li, Xingxing
    Ouyang, Lishan
    Wang, Longyan
    Liu, Dongxiao
    Wei, Xuejiao
    Tan, Peng
    Tu, Pengfei
    Hu, Zhongdong
    [J]. AMERICAN JOURNAL OF CHINESE MEDICINE, 2023, 51 (07): : 1627 - 1651
  • [22] Immunotherapy for metastatic cancer patients: the current status, limitations, obstacles and future directions
    Yau, Sau Han
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2020, 9 (02) : 121 - 125
  • [23] Bee Venom Immunotherapy: Current Status and Future Directions
    Zahirovic, Abida
    Luzar, Erne
    Molek, Peter
    Kruljec, Nika
    Lunder, Mojca
    [J]. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2020, 58 (03) : 326 - 341
  • [24] Immunotherapy in Cervical and Endometrial Cancer: Current Landscape and Future Directions
    Stefanoudakis, Dimitrios
    Karopoulou, Evaggelia
    Matsas, Alkis
    Katsampoula, Georgia Anna
    Tsarna, Ermioni
    Stamoula, Eleni
    Christopoulos, Panagiotis
    [J]. LIFE-BASEL, 2024, 14 (03):
  • [25] Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
    Xiong, Wei
    Zhao, Yunfeng
    Du, He
    Guo, Xuejun
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [26] The current status and prospect of immunotherapy in colorectal cancer
    Shu, Yefei
    Zheng, Song
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 26 (1) : 39 - 51
  • [27] Current status and prospect of immunotherapy for colorectal cancer
    Yang, Weiqing
    Zheng, Huifen
    Lv, Weibin
    Zhu, Yiping
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2023, 38 (01)
  • [28] Current Status of Immunotherapy for Lung Cancer and Future Perspectives
    Kim, Ho Cheol
    Choi, Chang-Min
    [J]. TUBERCULOSIS AND RESPIRATORY DISEASES, 2020, 83 (01) : 14 - 19
  • [29] Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions
    John L. Pfail
    Andrew B. Katims
    Parissa Alerasool
    John P. Sfakianos
    [J]. World Journal of Urology, 2021, 39 : 1319 - 1329
  • [30] Combination Immunotherapy for Mucosal Melanoma: Molecular Mechanism, Research Status, and Future Directions
    Yang, Jie
    Wang, Xuerui
    Meng, Yuan
    Zhu, Meiying
    Kong, Fanming
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2025, : 431 - 444